EXHIBIT 12.1
Halozyme Therapeutics, Inc.
Statement of Computation of Ratios
Nine Months Ended September 30, 2011 | ||||||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||||||
2006 | 2007 | 2008 | 2009 | 2010 | ||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Net loss | $ | (14,752 | ) | $ | (23,896 | ) | $ | (48,654 | ) | $ | (58,361 | ) | $ | (53,242 | ) | $ | (1,354 | ) | ||||||
Add: Fixed charges | 45 | 160 | 207 | 207 | 232 | 166 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Earnings as defined | $ | (14,707 | ) | $ | (23,736 | ) | $ | (48,447 | ) | $ | (58,154 | ) | $ | (53,010 | ) | $ | (1,188 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Fixed Charges and Preferred Stock Dividends: | ||||||||||||||||||||||||
Interest expense | $ | — | $ | — | $ | — | $ | 2 | $ | — | $ | — | ||||||||||||
Estimated interest component of rent expenses | 45 | 160 | 207 | 205 | 232 | 166 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total fixed charges | 45 | 160 | 207 | 207 | 232 | 166 | ||||||||||||||||||
Preferred stock dividends | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Total fixed charges and preferred stock dividends | $ | 45 | $ | 160 | $ | 207 | $ | 207 | $ | 232 | $ | 166 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to fixed charges (1) | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to combined fixed charges and preferred stock dividends (1) | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(1) | We reported a net loss for the years ended December 31, 2006, 2007, 2008, 2009, 2010 and the nine months ended September 30, 2011 and would have needed to generate additional income of approximately $14.8 million, $23.9 million, $48.7 million, $58.4 million, $53.2 million and $1.4 million respectively, to cover our fixed charges and combined fixed charges and preferred stock dividends of approximately $45,000, $160,000, $207,000, $207,000, $232,000 and $166,000, respectively. |